October 23, 2016
What happens when patients’ medications are switched for financial reasons instead of medical reasons? Does it affect their health? Their…
October 20, 2016
This month’s World Health Organization Open Sessions with INN Stakeholders explored the value, and the future, of the biological qualifier system. The Global Alliance for Patient Access was pleased to present to WHO officials and an international group of fellow stakeholders.
October 20, 2016
As ICER’s draft report acknowledges, plaque psoriasis is a common disease that can impact patients’ quality of life and daily…
October 18, 2016
Breast Cancer Awareness Month, celebrated this October, invites public dialogue about screening, risk factors and the value of early detection.
October 14, 2016
October marks the beginning of both the RSV viral season and RSV awareness month. The National Coalition for Infant Health is taking the opportunity to release a new “Fast Facts” educational resource on the virus, its impact, and its danger for infants, especially preemies whose health plans don’t cover preventive treatment.
October 13, 2016
Biosimilar medicines are being prescribed more and more freely across Europe. But access to, and use of, these new medicines differs greatly depending on which European country you live in.
October 12, 2016
Preliminary data from the Institute for Patient Access suggest what opponents of non-medical switching have long suspected: having medications switched for financial reasons could be bad news for patients with chronic diseases.
October 6, 2016
Since the advent of biosimilars, experts and pundits have debated how reduced biosimilar prices will be and just much savings the follow-on drugs will offer.
October 1, 2016
Millions of Americans and their families deal with the debilitating effects of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s.…
September 29, 2016
Innovative but costly anti-cancer drugs have spurred the development of several value assessments and cost frameworks, all designed to explore one question: Do the benefits of these treatments justify their price? Now, new research published in Health Affairs suggests that these treatments may significantly extend the life expectancy of some cancer patients.
